本文已被：浏览 38次 下载 22次
投稿时间：2024-10-17 网络发布日期：2025-03-20
投稿时间：2024-10-17 网络发布日期：2025-03-20
中文摘要: 目的 探讨卡瑞利珠单抗与含铂双药方案联合对晚期肺腺癌的疗效及对肿瘤标志物、免疫功能、2年生存率的影响。方法 回顾性选取2019年9月至2021年9月盐城市第三人民医院收治的109例晚期肺腺癌患者，依据治疗方式分为联合治疗组（n=55，卡铂+培美他塞+卡瑞利珠单抗治疗）、化疗组（n=54，卡铂+培美他塞治疗），比较其临床疗效及治疗前后肿瘤标志物水平、淋巴细胞亚群、不良反应及2年生存率。结果 治疗4个周期后，联合治疗组客观缓解率、疾病控制率高于化疗组（60.00% vs 31.48%, χ2=8.925, P=0.003; 85.45% vs 66.67%, χ2=5.295, P=0.021）；联合治疗组癌胚抗原（CEA）、鳞状上皮细胞癌抗原（SCC）、细胞角蛋白19片段抗原21-1（CFYRA21-1）、神经元特异性烯醇化酶（NSE）、糖类抗原（CA）125、CA199水平均低于化疗组（P＜0.05）；与化疗组比较，联合治疗组CD3+、CD4+、CD4+/CD8+水平高（P＜0.05）；联合治疗组反应性皮肤毛细血管增生症发生率高于化疗组（P＜0.05），两组其他不良反应发生率比较差异无统计学意义（P＞0.05）；两组的总生存（OS）、无进展生存（PFS）时间比较差异有统计学意义（P＜0.01），且联合治疗组2年OS率、PFS率较化疗组高（34.12% vs 28.33%， 46.57% vs 32.26%，P＜0.05）。结论 卡瑞利珠单抗联合含铂双药方案对晚期肺腺癌存在一定效果，可改善其肿瘤标志物水平、免疫功能，改善患者2年生存预后。
Abstract: Objective To analyze the effect of camrelizumab combined with platinum-containing dual-drug regimen in the treatment of advanced lung adenocarcinoma, and the influence on tumor markers, immune function and 2-year survival rate.Methods A retrospective study was conducted on 109 patients with advanced lung adenocarcinoma admitted to Yancheng Third Peoples Hospital from September 2019 to September 2021 were selected. They were divided into a combined treatment group (n=55, treatment with carboplatin+pemetrexed+camrelizumab) and a chemotherapy group (n=54, treatment with carboplatin+pemetrexed) according to their treatment methods. Clinical effects, tumor marker levels, lymphocyte subsets, adverse reactions, and 2-year survival rate were compared between the two groups. Results After 4 cycles of treatment, the objective remission rate and disease control rate in the combined treatment group were higher than those in the chemotherapy group （60.00% vs 31.48%, χ2=8.925, P=0.003; 85.45% vs 66.67%,χ2=5.295, P=0.021）. The levels of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment antigen 21-1 (CFYRA21-1), neuron-specific enolase (NSE), carbohydrate antigen(CA) 125 and CA199 in the combined treatment group were lower than those in the chemotherapy group (P＜0.05). Compared with the chemotherapy group, the CD3+, CD4+ and CD4+/CD8+ in the combined treatment group were higher(P＜0.05). The incidence of reactive cutaneous capillary endothelial proliferation in the combined treatment group was higher than that in the chemotherapy group (P＜0.05), but there was no statistically significant difference in the incidence of other adverse reactions between the two groups (P＞0.05). The overall survival (OS) time and progression-free-survival (PFS) time of the combined treatment group and the chemotherapy group showed a statistically significant differences (P＜0.01). The 2-year OS rate and PFS rate of the combined treatment group were higher than that of the chemotherapy group (34.12% vs 28.33%, 46.57% vs 32.26%，P＜0.05). Conclusion Camrelizumab combined with platinum-containing dual-drug regimen is effective in the treatment of advanced lung adenocarcinoma, which can improve patients tumor marker levels, immune function, and 2-year survival.
文章编号： 中图分类号：R734.2 文献标志码：A
基金项目:
附件
引用文本：
杭业，宋锦，陈金忠，毛义翔.卡瑞利珠单抗联合含铂双药方案治疗晚期肺腺癌的疗效[J].中国临床研究,2025,38(3):366-370.
杭业，宋锦，陈金忠，毛义翔.卡瑞利珠单抗联合含铂双药方案治疗晚期肺腺癌的疗效[J].中国临床研究,2025,38(3):366-370.